Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer
Abstract Androgens are a major driver of prostate cancer (PCa) and continue to be a critical treatment target for advanced disease, which includes castration therapy and antiandrogens. However, resistance to these therapies leading to metastatic castration-resistant prostate cancer (mCRPC), and the...
Guardado en:
Autores principales: | Madonna R. Peter, Misha Bilenky, Alastair Davies, Ruth Isserlin, Gary D. Bader, Neil E. Fleshner, Martin Hirst, Amina Zoubeidi, Bharati Bapat |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a0d4c3f1dab4fb8aab66b888d10d9ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Jingsong Zhang, et al.
Publicado: (2017) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Peter Arnold, et al.
Publicado: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016)